pp-226 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Sickle Cell Disease
Clinical stage: Phase 3
Modality: Small molecule pyruvate kinase activator
Mechanism & Target: PK activator increasing RBC ATP
Route & form: Oral
Differentiation: First-in-class PK activator for SCD
Manufacturer #39434
Clinical-stage biopharmaceutical company specializing in central nervous system disorders. Develops novel small molecules targeting psychiatric, neurological, and rare CNS conditions. Pursues multiple Phase 2 and Phase 3 programs through global development initiatives.
None